Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Gribben

Showing results (51-60 of 104) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|November 13, 2014
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphomaSophie Bernard, Damien Danglade, Laura Gardano, et al.
British Journal of Pharmacology|August 20, 2025
Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemiaYoana Arroyo-Berdugo, Antonella Di Mambro, Volker Behrends, et al.
Hemasphere|June 9, 2026
Lamin B1 safeguards the B cell genome and shapes lymphoma outcomeFilip Filipsky, Katarina B Chapman, Johannes Bloehdorn, et al.
Cancer Cell|September 6, 2017
Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid LeukemiaDiana Passaro, Alessandro Di Tullio, Ander Abarrategi, et al.
Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.
Cell Reports|May 12, 2021
Integrated OMICs unveil the bone-marrow microenvironment in human leukemiaDiana Passaro, Manuel Garcia-Albornoz, Giovanni Diana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Science Translational Medicine|June 22, 2022
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemiaWilliam Grey, Ana Rio-Machin, Pedro Casado, et al.
Leukemia|April 8, 2018
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsPedro Casado, Edmund H Wilkes, Farideh Miraki-Moud, et al.
Pageof 11

Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|November 13, 2014
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphomaSophie Bernard, Damien Danglade, Laura Gardano, et al.
British Journal of Pharmacology|August 20, 2025
Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemiaYoana Arroyo-Berdugo, Antonella Di Mambro, Volker Behrends, et al.
Hemasphere|June 9, 2026
Lamin B1 safeguards the B cell genome and shapes lymphoma outcomeFilip Filipsky, Katarina B Chapman, Johannes Bloehdorn, et al.
Cancer Cell|September 6, 2017
Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid LeukemiaDiana Passaro, Alessandro Di Tullio, Ander Abarrategi, et al.
Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.
Cell Reports|May 12, 2021
Integrated OMICs unveil the bone-marrow microenvironment in human leukemiaDiana Passaro, Manuel Garcia-Albornoz, Giovanni Diana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Science Translational Medicine|June 22, 2022
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemiaWilliam Grey, Ana Rio-Machin, Pedro Casado, et al.
Leukemia|April 8, 2018
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsPedro Casado, Edmund H Wilkes, Farideh Miraki-Moud, et al.
Pageof 11